Form 4: Avalo Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, Inc., sold 1,000 shares of common stock on July 27, 2026 for $20.00 per share.
Summary
- Option exercise/conversion: acquired 1,000 Common Stock at $12.65 ($12,650) on July 27, 2026; holds 52,776 after (Direct).
- Open-market sale: disposed of 1,000 Common Stock at $20.00 ($20,000) on July 27, 2026; holds 51,776 after (Direct).
- Option exercise/conversion: disposed of 1,000 Stock Option (Right to Buy) on July 27, 2026; holds 124,750 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $20,000 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Mittie Doyle — Officer (Chief Medical Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-27 | Option exercise/conversion | Common Stock | 1,000 | $13 | $12.7K | 52,776 |
| 2026-07-27 | Open-market sale | Common Stock | 1,000 | $20 | $20.0K | 51,776 |
| 2026-07-27 | Option exercise/conversion | Stock Option (Right to Buy) | 1,000 | — | — | 124,750 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-27 | Option exercise/conversion (1,000 shares) |
| 2026-07-27 | Open-market sale (1,000 shares) |
| 2026-07-27 | Option exercise/conversion (1,000 shares) |
Keywords
insider transaction, Form 4, AVTX, Avalo Therapeutics, Inc., bearish, Mittie Doyle
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.